Still, Jazz noted that the acquisition will be dilutive to both GAAP and non-GAAP adjusted net income per diluted share in 2021. With the addition of GW, we are excited to transform the lives of even more patients and their families.” “We believe Epidiolex has near-term blockbuster potential and expect the addition of Epidiolex and the GW pipeline to deliver double-digit revenue growth, accelerated revenue diversification and substantial shareholder value. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals. As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S. These investments will support the recent successful launches of both Xywav and Zepzelca, the ongoing growth of Epidiolex, the anticipated launches of JZP458 for ALL or LBL and Xywav in idiopathic hypersomnia, and the rolling launch of Epidyolex in Europe. Our guidance reflects strong execution across our commercial portfolio, continued investment in both our ongoing and planned launches, and strategic investments in R&D to advance therapies to patients in critical need of new treatment options. “We expect 2021 to be another exciting, productive, and transformational year for Jazz and are pleased to update our guidance to include the addition of GW. The 2021 guidance for a GAAP net loss is in the range of $290 – $125 million. Jazz said it expects to generate 65% of 2022 revenues from products that have been launched or acquired since 2019. That has been increased as of June 17, 2021, to a range of $3.0 to $3.1 billion. The guidance for revenue was in the range of $2.5 – $2.7 billion. To read this article on click here.Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Investors should take the time to consider JAZZ for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. JAZZ has an average earnings surprise of 12.8%. The Zacks Consensus Estimate has increased $0.57 to $17.05 per share. 11 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2022. Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. Shares of Jazz Pharmaceuticals are trading at a forward earnings multiple of 8.8X, as well as a PEG Ratio of 1.1, a Price/Cash Flow ratio of 6.5X, and a Price/Sales ratio of 2.8X. JAZZ boasts a Value Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Xywav was also approved for treating idiopathic hypersomnia (IH). Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |